These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20101414)

  • 1. Impact of changes in reimbursement policies and institutional practice algorithm for utilization of erythropoietic-stimulating agents on treatment patterns and costs in anemic lymphoma patients.
    Lal LS; Raju A; Miller LA; Chen H; Arbuckle R; Sansgiry SS
    Support Care Cancer; 2010 Feb; 19(2):251-9. PubMed ID: 20101414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusions increase with nationally driven reimbursement changes of erythropoiesis stimulating agents for chemotherapy-induced anemia.
    Yu JM; Shord SS; Cuellar S
    J Oncol Pharm Pract; 2011 Dec; 17(4):360-5. PubMed ID: 20826550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia.
    Polsky D; Eremina D; Hess G; Hill J; Hulnick S; Roumm A; Whyte JL; Kallich J
    Pharmacoeconomics; 2009; 27(9):755-65. PubMed ID: 19757869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the use of erythropoiesis-stimulating agents (ESAs) and red blood cell transfusion in patients with cancer amidst regulatory and reimbursement changes.
    Gawade PL; Berlin JA; Henry DH; Tomita D; Brooks BD; Franklin J; Bradbury BD; Critchlow CW
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1357-1366. PubMed ID: 28809079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to guidelines for use of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia: results of a retrospective study of an electronic medical-records database in the United States, 2002-2006.
    Luo W; Nordstrom BL; Fraeman K; Nordyke R; Ranganathan G; Linz HE; Winterkorn A; Stokes M; Ross SD; Knopf K
    Clin Ther; 2008 Dec; 30(12):2423-35. PubMed ID: 19167601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F; McKenzie RS; Bookhart BK; Laliberté F; Duh MS; Tak Piech C; Lefebvre P
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Centers for Medicare & Medicaid Services national coverage determination on erythropoiesis-stimulating agent and transfusion use in chemotherapy-treated cancer patients.
    Arneson TJ; Li S; Gilbertson DT; Bridges KR; Acquavella JF; Collins AJ
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):857-64. PubMed ID: 22450901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. End of an era for erythropoiesis-stimulating agents in oncology.
    Schoen MW; Hoque S; Witherspoon BJ; Schooley B; Sartor O; Yang YT; Yarnold PR; Knopf KB; Hrushesky WJM; Dickson M; Chen BJ; Nabhan C; Bennett CL
    Int J Cancer; 2020 May; 146(10):2829-2835. PubMed ID: 32037527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
    Reitan JF; van Breda A; Corey-Lisle PK; Shreay S; Cong Z; Legg J
    Clin Drug Investig; 2013 May; 33(5):383-9. PubMed ID: 23553358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions.
    Hess G; Nordyke RJ; Hill J; Hulnick S
    Am J Hematol; 2010 Nov; 85(11):838-43. PubMed ID: 20976794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L; Shiffman R; Tomita D; Stolshek B; Rossi G; Adamson R
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Erythropoiesis-stimulating agent use and blood transfusions for chemotherapy-induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
    Vega A; Zhang R; Wong HL; Wernecke M; Alexander M; Feng Y; Lo AC; Lufkin B; Ryan Q; Izem R; MaCurdy TE; Kelman JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2021 May; 30(5):626-635. PubMed ID: 33534188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoiesis-stimulating agent use after changes in medicare reimbursement policies.
    Hershman DL; Neugut AI; Shim JJ; Glied S; Tsai WY; Wright JD
    J Oncol Pract; 2014 Jul; 10(4):264-9. PubMed ID: 24737875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses.
    Vansteenkiste J; Glaspy J; Henry D; Ludwig H; Pirker R; Tomita D; Collins H; Crawford J
    Lung Cancer; 2012 Jun; 76(3):478-85. PubMed ID: 22277104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidemiology of Chemotherapy-Induced Anemia in Patients with Non-Hodgkin Lymphoma.
    Cannavale K; Xu H; Xu L; Sattayapiwat O; Rodriguez R; Bohac C; Page J; Chao C
    Perm J; 2019; 23():. PubMed ID: 31314738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial.
    Vansteenkiste J; Hedenus M; Gascon P; Bokemeyer C; Ludwig H; Vermorken J; Hamilton L; Bridges K; Pujol B
    BMC Cancer; 2009 Sep; 9():311. PubMed ID: 19728887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reassessments of ESAs for cancer treatment in the US and Europe.
    Bennett CL; McKoy JM; Henke M; Silver SM; MacDougall IC; Birgegård G; Luminari S; Casadevall N; Schellekens H; Sartor O; Lai SY; Armitage JO
    Oncology (Williston Park); 2010 Mar; 24(3):260-8. PubMed ID: 20394138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia.
    Hoque S; Chen BJ; Schoen MW; Carson KR; Keller J; Witherspoon BJ; Knopf KB; Yang YT; Schooley B; Nabhan C; Sartor O; Yarnold PR; Ray P; Bobolts L; Hrushesky WJ; Dickson M; Bennett CL
    PLoS One; 2020; 15(6):e0234541. PubMed ID: 32584835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
    Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.